A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

NCT07552077 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
15
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Palvella Therapeutics, Inc.